• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by TG Therapeutics Inc.

    1/8/25 11:29:53 AM ET
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TGTX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 5)


    TG Therapeutics Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    88322Q108

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    88322Q108


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    266,881.00
    7Sole Dispositive Power

    15,162,429.00
    8Shared Dispositive Power

    434,051.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    15,596,480.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.01 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    TG Therapeutics Inc
    (b)Address of issuer's principal executive offices:

    2 Gansevoort Street 9th Floor, New York, NY, 10014
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd., Malvern, PA 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    88322Q108
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    15596480
    (b)Percent of class:

    10.01  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    266881

     (iii) Sole power to dispose or to direct the disposition of:

    15162429

     (iv) Shared power to dispose or to direct the disposition of:

    434051

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:01/08/2025
    Get the next $TGTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TGTX

    DatePrice TargetRatingAnalyst
    10/29/2024$50.00Buy
    TD Cowen
    8/2/2023$16.00 → $12.00Sell → Neutral
    Goldman
    6/26/2023$55.00 → $40.00Buy
    Jefferies
    5/20/2022$5.00Underperform
    BofA Securities
    2/23/2022$49.00 → $35.00Buy
    B. Riley Securities
    1/28/2022$70.00 → $68.00Buy
    HC Wainwright & Co.
    1/24/2022$75.00 → $70.00Buy
    HC Wainwright & Co.
    12/1/2021$55.00 → $36.00Outperform
    Evercore ISI Group
    More analyst ratings

    $TGTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance

      First quarter 2025 BRIUMVI U.S. net revenue of $119.7 million Raises full year 2025 global net revenue target to approximately $575 million and raises full year BRIUMVI U.S. net revenue target to approximately $560 million Conference call to be held today, Monday, May 5, 2025, at 8:30 AM ET    NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) (the Company or TG Therapeutics) today announced its financial results for the first quarter of 2025, along with recent company developments and provided an update on 2025 revenue guidance. Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated, "2025 is off to a strong start, and I'm incredibly

      5/5/25 7:00:00 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update

      NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Monday, May 5, 2025, at 8:30 AM ET to discuss results for the first quarter of 2025 and provide a business outlook for the remainder of 2025. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An au

      4/30/25 7:30:00 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

      NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology 2025 annual meeting. Links to each presentation are included below. Michael S. Weiss, Chief Executive Officer and Chairman of TG Therapeutics stated, "We were pleased to share three presentations yesterday which we believe demonstrate our continued commitment to improving the patient experience and understanding the long term and real-world profile of BRIUMVI." Mr. Weiss continued, "The results of the retrospective ENAMOR surv

      4/8/25 7:30:00 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TGTX
    SEC Filings

    See more
    • SEC Form 10-Q filed by TG Therapeutics Inc.

      10-Q - TG THERAPEUTICS, INC. (0001001316) (Filer)

      5/9/25 4:31:06 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - TG THERAPEUTICS, INC. (0001001316) (Filer)

      5/5/25 7:31:59 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by TG Therapeutics Inc.

      DEFA14A - TG THERAPEUTICS, INC. (0001001316) (Filer)

      4/30/25 4:18:47 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TGTX
    Financials

    Live finance-specific insights

    See more

    $TGTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $TGTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $TGTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $TGTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance

      First quarter 2025 BRIUMVI U.S. net revenue of $119.7 million Raises full year 2025 global net revenue target to approximately $575 million and raises full year BRIUMVI U.S. net revenue target to approximately $560 million Conference call to be held today, Monday, May 5, 2025, at 8:30 AM ET    NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) (the Company or TG Therapeutics) today announced its financial results for the first quarter of 2025, along with recent company developments and provided an update on 2025 revenue guidance. Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated, "2025 is off to a strong start, and I'm incredibly

      5/5/25 7:00:00 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update

      NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Monday, May 5, 2025, at 8:30 AM ET to discuss results for the first quarter of 2025 and provide a business outlook for the remainder of 2025. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An au

      4/30/25 7:30:00 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

      Fourth quarter and full year 2024 BRIUMVI U.S. net revenue of $103.6 million and $310 million, respectively Target guidance of approximately $540 million in total global revenue for 2025 Conference call to be held today, March 3, 2025, at 8:30 AM ET NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) (the Company or TG Therapeutics) today announced its financial results for the fourth quarter and full year ended December 31, 2024, along with recent company developments. Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated,

      3/3/25 7:00:00 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Hume Daniel gifted 62,459 shares, decreasing direct ownership by 26% to 178,030 units (SEC Form 4)

      4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)

      3/18/25 5:01:41 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Charney Laurence N gifted 6,000 shares, decreasing direct ownership by 3% to 201,479 units (SEC Form 4)

      4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)

      3/11/25 5:00:42 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Weiss Michael S was granted 750,000 shares, increasing direct ownership by 6% to 13,824,929 units (SEC Form 4)

      4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)

      1/30/25 5:17:24 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TD Cowen initiated coverage on TG Therapeutics with a new price target

      TD Cowen initiated coverage of TG Therapeutics with a rating of Buy and set a new price target of $50.00

      10/29/24 6:30:43 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics upgraded by Goldman with a new price target

      Goldman upgraded TG Therapeutics from Sell to Neutral and set a new price target of $12.00 from $16.00 previously

      8/2/23 8:51:11 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies resumed coverage on TG Therapeutics with a new price target

      Jefferies resumed coverage of TG Therapeutics with a rating of Buy and set a new price target of $40.00 from $55.00 previously

      6/26/23 9:08:22 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by TG Therapeutics Inc.

      SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)

      11/14/24 7:45:34 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by TG Therapeutics Inc. (Amendment)

      SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)

      2/14/24 3:30:53 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by TG Therapeutics Inc. (Amendment)

      SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)

      1/25/24 11:29:01 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

      Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (SUPPL-11) with active ingredient UBLITUXIMAB-XIIY has changed to 'Approval' on 10/30/2024. Application Category: BLA, Application Number: 761238, Application Classification:

      10/31/24 4:38:40 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

      Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (ORIG-1) with active ingredient UBLITUXIMAB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761238, Application Classification:

      12/28/22 12:54:09 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for UKONIQ

      Submission status for TG THERAPEUTICS INC's drug UKONIQ (ORIG-1) with active ingredient UMBRALISIB TOSYLATE has changed to 'Approval' on 02/05/2021. Application Category: NDA, Application Number: 213176, Application Classification: Type 1 - New Molecular Entity

      2/9/21 12:05:59 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TGTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from

      9/6/24 6:43:00 PM ET
      $AAL
      $ADMA
      $ADNT
      $AMCX
      Air Freight/Delivery Services
      Consumer Discretionary
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care